Four Directors at Tidewater Inc sold 356,017 shares at between 107.210USD and 109.009USD. The significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Array Technologies, Inc. Reports Financial Results for the First Quarter 2024 – Achieves record gross margin and $2.1 billion of executed contracts and awarded orders First Quarter 2024 Highlights Revenue of $153.4 millionGross Margin of 35.9%Adjusted gross margin of 38.3%(1)Net loss to common shareholders of $11.3 millionAdjusted EBITDA(1) of $26.2 millionBasic and diluted net loss per share of $0.07Adjusted diluted net income per share(1) of $0.06 ALBUQUERQUE, N.M., May 09, 2024 (GLOBE NEWSWIRE) -- Array Technologies (NASDAQ: ARRY) (“Array” or “the Company”), a leading...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on May 6, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,150 shares of its common stock to seven new employees. These inducement RSUs are subject to the terms of the ...
AVENTURA, Fla.--(BUSINESS WIRE)-- Immersion Corporation (Nasdaq: IMMR), a leading developer and provider of technologies for haptics, today reported financial results for the first quarter ended March 31, 2024. First Quarter Financial Summary1: Total revenues of $43.8 million, compared to $7.1 million in the first quarter of 2023. GAAP net income was $18.7 million, or $0.59 per diluted share, compared to GAAP net income of $8.3 million, or $0.25 per diluted share, in the first quarter of 2023. GAAP operating expenses of $27.2 million in the first quarter of 2024, compared to $3.8 mi...
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) mul...
MACON, Ga.--(BUSINESS WIRE)-- Blue Bird Corporation (“Blue Bird”) (Nasdaq: BLBD), the leader in electric and low-emission school buses, announced today its fiscal 2024 second quarter results. Highlights (in millions except Unit Sales and EPS data) Three Months Ended March 30, 2024 B/(W) Prior Year Six Months Ended March 30, 2024 B/(W) Prior Year Unit Sales 2,254 (50 ) 4,383 122 GAAP Measures: ...
NEW YORK--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the first quarter ended March 31, 2024. First Quarter Highlights and Outlook First quarter worldwide revenue of $37.2 million. 2024 revenue guidance remains $174 million to $184 million, an increase of 5% to 11% over 2023. Guidance does not include revenue from Motiva Implants® in the United States, which is expected in 2024. Gross...
Axsome Therapeutics to Present at Upcoming Investor Conferences NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences. The presentation details are as follows: RBC Capital Markets 2024 Global Healthcare Conference, on Tuesday, May 14, at 1:35 p.m. Eastern Time. Dr. Tabuteau will participate in ...
Two Directors at Carpenter Technology Corp sold after exercising options/sold 31,802 shares at between 100.568USD and 102.110USD. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trade...
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update -- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 -- -- Phase 3 trial evaluating setmelanotide in hypothalamic obesity remains on track for topline data readout in 1H 2025; dosing of first patients in Japan anticipated in 2Q 2024 -- -- Secured $150 million in convertible preferred stock fina...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.